#2020 vision wills point trial#

After unilateral injection of the gene therapy, evidence of viral vector DNA was discovered in the anterior segment, retina, and optic nerve of the contralateral uninjected eye. In order to explain the unexpected bilateral improvement of visual function, this paper also reports the results of a parallel non-human primate study.

#2020 vision wills point trial#

While there was hope for improvement in the eye injected with the proper gene, the unexpected finding in the REVERSE trial was bilateral improvement in visual acuity from a unilateral injection.

One eye was injected with the gene and the other with a sham injection. The gene therapy trial, which took place at seven centers worldwide including at Wills Eye Hospital in Philadelphia, involved treating patients over age 15 with LUMEVOQВ® (Gensight Biologics, Paris, France) gene therapy for a mutation in the ND4 mitochondrial gene. REVERSE is a randomized, double masked, sham-controlled, multi-center, phase III clinical trial that evaluated the efficacy of a single intravitreal injection of ND4 in subjects with visual loss from LHON.

Males are about four to five times more likely than females to be affected with the condition. LHON most often afflicts people with rapid onset of blindness in the prime of their life - men and women in their teens or twenties. Philadelphia PA вЂ“ New data published in the Journal Science Translational Medicine shows encouraging results in a worldwide clinical trial for patients diagnosed with the neuro-degenerative blinding eye disease Leber Hereditary Optic Neuropathy (LHON.) The disease is an inherited form of vision loss estimated to affect 1 in 30,000 to 50,000 individuals.